IVIG Demonstrates Improved Response Rates in Autoimmune Encephalitis Trial

NeurologyLive·Apr 27

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A trial has found that intravenous immunoglobulin (ivig) shows improved response rates in treating autoimmune encephalitis. The results indicate a positive outcome for the use of ivig in this context. The trial's findings suggest ivig may be an effective treatment option for autoimmune encephalitis.

Full coverage

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma

CancerNetwork·Jun 18

Advances in the treatment of autoimmune nodopathy: based on treatment strategies of CIDP

Frontiers·Feb 24

Does the Use of Intravenous Immunoglobulin Improve Clinical Outcomes in Adults With Autoimmune Encephalitis? A Systematic Review

Wiley Online Library·May 12

Lyme Disease as a Potential Precursor to Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report

Cureus·Feb 27

Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome

Frontiers·Mar 18

View original report at NeurologyLive ↗

Fetching the latest headlines…